MedTrace Logo

A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers

NCT07650383 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-06-16

No results posted yet for this study

Summary

To evaluate the safety, the tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of ENERGI-F705 Tablets in healthy subjects.

Conditions

  • Health Adult Subjects

Interventions

DRUG

ENERGI-F705 Tablets 60 mg

ENERGI-F705 tablets administered orally under fasting conditions.

DRUG

ENERGI-F705 Tablets 120 mg

ENERGI-F705 tablets administered orally under fasting conditions.

DRUG

Vehicle Control

Matched vehicle control tablets administered orally under fasting conditions.

Sponsors & Collaborators

  • Energenesis Biomedical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2025-05-06
Completion
2025-11-19

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07650383 on ClinicalTrials.gov